Galecto has a Cash Ratio of 6.29. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Galecto's Cash Ratio or its related term are showing as below:
GLTO'
s Cash Ratio Range Over the Past 10 Years
Min: 1.42 Med: 9.02 Max: 29.39
Current: 6.29
During the past 6 years, Galecto's highest Cash Ratio was 29.39. The lowest was 1.42. And the median was 9.02.
GLTO's Cash Ratio is ranked better than 71.41% of 1525
companies
in the Biotechnology industry
Industry Median: 2.94
vs GLTO: 6.29
Galecto Cash Ratio Historical Data
The historical data trend for Galecto's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Galecto's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galecto's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Galecto's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Galecto's Cash Ratio falls into.
Galecto Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Galecto's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galecto (NAS:GLTO) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Galecto Cash Ratio Related Terms
Thank you for viewing the detailed overview of Galecto's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis-related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLTO has been successfully added to your 